Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2007 2
2008 9
2009 4
2010 2
2012 3
2013 1
2014 2
2015 4
2016 2
2017 3
2018 4
2019 3
2020 13
2021 11
2022 22
2023 25
2024 32
2025 25
2026 5

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

153 results

Results by year

Filters applied: . Clear all
Page 1
Plasma p-tau231 and p-tau217 as state markers of amyloid-beta pathology in preclinical Alzheimer's disease.
Milà-Alomà M, Ashton NJ, Shekari M, Salvadó G, Ortiz-Romero P, Montoliu-Gaya L, Benedet AL, Karikari TK, Lantero-Rodriguez J, Vanmechelen E, Day TA, González-Escalante A, Sánchez-Benavides G, Minguillon C, Fauria K, Molinuevo JL, Dage JL, Zetterberg H, Gispert JD, Suárez-Calvet M, Blennow K. Milà-Alomà M, et al. Nat Med. 2022 Sep;28(9):1797-1801. doi: 10.1038/s41591-022-01925-w. Epub 2022 Aug 11. Nat Med. 2022. PMID: 35953717 Free PMC article.
In the ALFA+ cohort, all tested plasma biomarkers (p-tau181, p-tau217, p-tau231, GFAP, NfL and Abeta42/40) were significantly changed in preclinical Alzheimer's disease. However, plasma p-tau231 reached abnormal levels with the lowest Abeta burden. Pla …
In the ALFA+ cohort, all tested plasma biomarkers (p-tau181, p-tau217, p-tau231, GFAP, NfL and Abeta42/40) were signifi …
The effect of berberine supplementation on obesity parameters, inflammation and liver function enzymes: A systematic review and meta-analysis of randomized controlled trials.
Asbaghi O, Ghanbari N, Shekari M, Reiner Ž, Amirani E, Hallajzadeh J, Mirsafaei L, Asemi Z. Asbaghi O, et al. Clin Nutr ESPEN. 2020 Aug;38:43-49. doi: 10.1016/j.clnesp.2020.04.010. Epub 2020 May 6. Clin Nutr ESPEN. 2020. PMID: 32690176

Berberine treatment moderately but significantly decreased body weight (WMD = -2.07 kg, 95% CI -3.09, -1.05, P < 0.001), body mass index (BMI) (WMD = -0.47 kg/m(2), 95% CI -0.70, -0.23, P < 0.001), waist circumference (WC) (WMD = -1.08 cm, 95% CI -1.97, -0.19,

…

Berberine treatment moderately but significantly decreased body weight (WMD = -2.07 kg, 95% CI -3.09, -1.05, P < 0.001), body mass

…
Penetrance of pathogenic genetic variants associated with premature ovarian insufficiency.
Shekari S, Stankovic S, Gardner EJ, Hawkes G, Kentistou KA, Beaumont RN, Mörseburg A, Wood AR, Prague JK, Mishra GD, Day FR, Baptista J, Wright CF, Weedon MN, Hoffmann ER, Ruth KS, Ong KK, Perry JRB, Murray A. Shekari S, et al. Nat Med. 2023 Jul;29(7):1692-1699. doi: 10.1038/s41591-023-02405-5. Epub 2023 Jun 22. Nat Med. 2023. PMID: 37349538
We found evidence of haploinsufficiency effects in several genes, including TWNK (1.54 years earlier menopause, P = 1.59 10(-6)) and SOHLH2 (3.48 years earlier menopause, P = 1.03 10(-4)). Collectively, our results suggest that, for the vast majority of women, P …
We found evidence of haploinsufficiency effects in several genes, including TWNK (1.54 years earlier menopause, P = 1.59 10(-6)) an …
Astrocyte biomarkers GFAP and YKL-40 mediate early Alzheimer's disease progression.
Pelkmans W, Shekari M, Brugulat-Serrat A, Sánchez-Benavides G, Minguillón C, Fauria K, Molinuevo JL, Grau-Rivera O, González Escalante A, Kollmorgen G, Carboni M, Ashton NJ, Zetterberg H, Blennow K, Suarez-Calvet M, Gispert JD; ALFA study. Pelkmans W, et al. Alzheimers Dement. 2024 Jan;20(1):483-493. doi: 10.1002/alz.13450. Epub 2023 Sep 10. Alzheimers Dement. 2024. PMID: 37690071 Free PMC article.
RESULTS: Cerebrospinal fluid (CSF) amyloid beta (Abeta)(42/40) was associated with Abeta aggregation on positron emission tomography (PET) and with CSF p-tau(181) , which was in turn directly associated with CSF neurofilament light (NfL). Plasma glial fibrillary acidic pro …
RESULTS: Cerebrospinal fluid (CSF) amyloid beta (Abeta)(42/40) was associated with Abeta aggregation on positron emission tomography (PET) a …
Genetic links between ovarian ageing, cancer risk and de novo mutation rates.
Stankovic S, Shekari S, Huang QQ, Gardner EJ, Ivarsdottir EV, Owens NDL, Mavaddat N, Azad A, Hawkes G, Kentistou KA, Beaumont RN, Day FR, Zhao Y, Jonsson H, Rafnar T, Tragante V, Sveinbjornsson G, Oddsson A, Styrkarsdottir U, Gudmundsson J, Stacey SN, Gudbjartsson DF; Breast Cancer Association Consortium; Kennedy K, Wood AR, Weedon MN, Ong KK, Wright CF, Hoffmann ER, Sulem P, Hurles ME, Ruth KS, Martin HC, Stefansson K, Perry JRB, Murray A. Stankovic S, et al. Nature. 2024 Sep;633(8030):608-614. doi: 10.1038/s41586-024-07931-x. Epub 2024 Sep 11. Nature. 2024. PMID: 39261734 Free PMC article.
Differences Between Plasma and Cerebrospinal Fluid Glial Fibrillary Acidic Protein Levels Across the Alzheimer Disease Continuum.
Benedet AL, Milà-Alomà M, Vrillon A, Ashton NJ, Pascoal TA, Lussier F, Karikari TK, Hourregue C, Cognat E, Dumurgier J, Stevenson J, Rahmouni N, Pallen V, Poltronetti NM, Salvadó G, Shekari M, Operto G, Gispert JD, Minguillon C, Fauria K, Kollmorgen G, Suridjan I, Zimmer ER, Zetterberg H, Molinuevo JL, Paquet C, Rosa-Neto P, Blennow K, Suárez-Calvet M; Translational Biomarkers in Aging and Dementia (TRIAD) study, Alzheimer’s and Families (ALFA) study, and BioCogBank Paris Lariboisière cohort. Benedet AL, et al. JAMA Neurol. 2021 Dec 1;78(12):1471-1483. doi: 10.1001/jamaneurol.2021.3671. JAMA Neurol. 2021. PMID: 34661615 Free PMC article.
Other measurements included levels of CSF amyloid-beta 42/40 (Abeta42/40), phosphorylated tau181 (p-tau181), neurofilament light (NfL), Chitinase-3-like protein 1 (YKL40), and soluble triggering receptor expressed on myeloid cells 2 (sTREM2) and levels of plasma p-t …
Other measurements included levels of CSF amyloid-beta 42/40 (Abeta42/40), phosphorylated tau181 (p-tau181), neurofilament light (NfL …
Tau PET positivity in individuals with and without cognitive impairment varies with age, amyloid-β status, APOE genotype and sex.
Ossenkoppele R, Coomans EM, Apostolova LG, Baker SL, Barthel H, Beach TG, Benzinger TLS, Betthauser T, Bischof GN, Bottlaender M, Bourgeat P, den Braber A, Brendel M, Brickman AM, Cash DM, Carrillo MC, Coath W, Christian BT, Dickerson BC, Dore V, Drzezga A, Feizpour A, van der Flier WM, Franzmeier N, Frisoni GB, Garibotto V, van de Giessen E, Domingo-Gispert J, Gnoerich J, Gu Y, Guan Y, Hanseeuw BJ, Harrison TM, Jack CR, Jaeger E, Jagust WJ, Jansen WJ, La Joie R, Johnson KA, Johnson SC, Kennedy IA, Kim JP, van Laere K, Lagarde J, Lao P, Luchsinger JA, Kern S, Kreisl WC, Malotaux V, Malpetti M, Manly JJ, Mao X, Mattsson-Carlgren N; Mayo Clinic Study on Aging; Messerschmidt K, Minguillon C, Mormino EM, O'Brien JT, Palmqvist S, Peretti DE, Petersen RC, Pijnenburg YAL, Pontecorvo MJ, Poirier J; PREVENT-AD Research Group; Rabinovici GD, Rahmouni N, Risacher SL, Rosa-Neto P, Rosen H, Rowe CC, Rowe JB, Rullmann M, Salman Y, Sarazin M, Saykin AJ, Schneider JA, Schöll M, Schott JM, Seo SW, Serrano GE, Shcherbinin S, Shekari M, Skoog I, Smith R, Sperling RA, Spruyt L, Stomrud E, Strandberg O, Therriault J, Xie F, Vandenberghe R, Villemagne VL, Villeneuve S, Visser PJ, Vossler H, Young CB, G… See abstract for full author list ➔ Ossenkoppele R, et al. Nat Neurosci. 2025 Aug;28(8):1610-1621. doi: 10.1038/s41593-025-02000-6. Epub 2025 Jul 16. Nat Neurosci. 2025. PMID: 40670684 Free PMC article.
Plasma p-tau212 identifies cognitively unimpaired individuals with emerging amyloid-beta pathology.
Kac PR, González-Escalante A, Milà-Alomà M, Ashton NJ, Shekari M, Ortiz-Romero P, Turton M, Harrison P, Zetterberg H, Gispert JD, Karikari TK, Suárez-Calvet M, Blennow K. Kac PR, et al. J Neurol. 2025 Dec 25;273(1):48. doi: 10.1007/s00415-025-13572-5. J Neurol. 2025. PMID: 41447416 Free PMC article.
We benchmarked plasma p-tau212 against p-tau181, p-tau217, and p-tau231 by comparing their accuracies and fold changes for detecting brain amyloidosis. ...Discrimination performance of the biomarkers to differentiate amyloid PET-positive from amyloid P …
We benchmarked plasma p-tau212 against p-tau181, p-tau217, and p-tau231 by comparing their accuracies and fold c …
P-tau235: a novel biomarker for staging preclinical Alzheimer's disease.
Lantero-Rodriguez J, Snellman A, Benedet AL, Milà-Alomà M, Camporesi E, Montoliu-Gaya L, Ashton NJ, Vrillon A, Karikari TK, Gispert JD, Salvadó G, Shekari M, Toomey CE, Lashley TL, Zetterberg H, Suárez-Calvet M, Brinkmalm G, Rosa Neto P, Blennow K. Lantero-Rodriguez J, et al. EMBO Mol Med. 2021 Dec 7;13(12):e15098. doi: 10.15252/emmm.202115098. Epub 2021 Nov 2. EMBO Mol Med. 2021. PMID: 34725927 Free PMC article.
Alzheimer's disease (AD) is characterised by a long preclinical phase. Although phosphorylated tau (p-tau) species such as p-tau217 and p-tau231 provide accurate detection of early pathological changes, other biomarkers capable of staging disease progression …
Alzheimer's disease (AD) is characterised by a long preclinical phase. Although phosphorylated tau (p-tau) species such as p-t …
A plasma biomarker panel for detecting early amyloid-β accumulation and its changes in middle-aged cognitively unimpaired individuals at risk for Alzheimer's disease.
González-Escalante A, Milà-Alomà M, Brum WS, Ashton NJ, Ortiz-Romero P, Shekari M, Campo MD, Anastasi F, Quijano-Rubio C, Kollmorgen G, Minguillón C, Sánchez-Benavides G, Grau-Rivera O, Gispert JD, Zetterberg H, Vilor-Tejedor N, Blennow K, Suárez-Calvet M. González-Escalante A, et al. EBioMedicine. 2025 Jun;116:105741. doi: 10.1016/j.ebiom.2025.105741. Epub 2025 May 24. EBioMedicine. 2025. PMID: 40414160 Free PMC article.
All plasma biomarkers differed between Abeta-positive and -negative individuals, with plasma Abeta42/40, p-tau217, p-tau181/Abeta42, and p-tau217/Abeta42 showing the best performance in detecting A+ CU individuals. ...INTERPRETATION: In CU individuals, severa …
All plasma biomarkers differed between Abeta-positive and -negative individuals, with plasma Abeta42/40, p-tau217, p-tau181/Ab …
153 results